Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Fig. 4

Kaplan–Meier estimates of probability of overall survival in patients with metastatic breast cancer. Joint analysis of A circulating tumour cells and circulating free DNA (p < 0.0001, chi-square = 33.718; hazard ratio for patients with ≥ 5 CTCs and < 0.306 ng/μl, 2.232 with 95% CI = 1.232–4.042; hazard ratio for patients with < 5 CTCs and ≥ 0.306 ng/μl, 1.479 with 95% CI = 0.726–3.010; hazard ratio for patients with ≥ 5 CTCs and ≥ 0.306 ng/μl, 4.047 with 95% CI = 2.394–6.841) and B levels of CA15-3 and AP (p < 0.0001; chi-square = 37.349; hazard ratio for patients with ≥ 32 U/mL and < 130 IU/L, 2.519 with 95% CI = 1.425–4.453; hazard ratio for patients with ≥ 32 U/mL and ≥ 130 IU/L, 5.568 with 95% CI = 3.033–10.223). Group with < 32 U/mL and ≥ 130 IU/L omitted in Fig. 5b because the low number of patients, and included into group with ≥ 32 U/mL and ≥ 130 IU/L. p value obtained by the log-rank test. Hazard ratio and 95% CI obtained by Cox proportional-hazards regression analysis

Back to article page